Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma
SUPN•Outlook
- Supernus raises 2026 total revenue guidance to $860 mln-$890 mln from $840 mln-$870 mln
- Company now expects 2026 adjusted operating earnings of $150 mln-$180 mln, up from $140 mln-$170 mln
- ONAPGO 2026 net sales forecast maintained at $55 mln-$70 mln
Result drivers
- Growth products - Revenue growth was driven by higher net sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO
- Qelbree prescription volume - Qelbree net sales rose 15% yr/yr, primarily due to increased prescription volumes in both adult and pediatric populations
- ZURZUVAE collaboration revenue - Collaboration revenue from ZURZUVAE contributed to growth, with U.S. sales reported by Biogen up 53% yr/yr and prescriptions up 62%
Quarterly results and merger plans
- U.S. CNS drugmaker's Q2 revenue rose 32% yr/yr, driven by growth products
- Adjusted operating earnings for Q2 beat analyst expectations
- Company to merge with Indivior Pharmaceuticals in all-stock deal
